Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk. 15 245 patients, aged...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) 2004-06, Vol.363 (9426), p.2022-2031 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2031 |
|---|---|
| container_issue | 9426 |
| container_start_page | 2022 |
| container_title | The Lancet (British edition) |
| container_volume | 363 |
| creator | Julius, Stevo Kjeldsen, Sverre E Weber, Michael Brunner, Hans R Ekman, Steffan Hansson, Lennart Hua, Tsushung Laragh, John McInnes, Gordon T Mitchell, Lada Plat, Francis Schork, Anthony Smith, Beverly Zanchetti, Alberto |
| description | The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.
15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4–2 years.
Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p |
| doi_str_mv | 10.1016/S0140-6736(04)16451-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2069920953</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0140673604164519</els_id><sourcerecordid>657591711</sourcerecordid><originalsourceid>FETCH-LOGICAL-c468t-f64cf2db5d7bbca9cac9fa355db7a9c46bb7780e862f9221e17ef155c68c95283</originalsourceid><addsrcrecordid>eNqFkU1v1DAQhi0EokvhJ4AsuMAhYHv9EXNBVVU-pJV6gCJulmNPGpdNHGxnUf8FPxlvdwUnxGnk0fPOaPwg9JSS15RQ-eYzoZw0Uq3lS8JfUckFbfQ9tKJc8UZw9e0-Wv1BTtCjnG8IIVwS8RCdUMGI0oKt0K_Lpbg4QsZhwsPtDKnAlMMO8GxLgKlkbAsewvWAnU0-xJ3NbtnahFPI33FJYAt4_DOUASe4DmNN487m2osT3tlttqnYCceE7biNPsxhgre4DIC_nm2uLnCyk49j2AdKCnb7GD3oawqeHOspunp_8eX8Y7O5_PDp_GzTOC7b0vSSu575TnjVdc5qZ53u7VoI36n64rLrlGoJtJL1mjEKVEFPhXCydfXwdn2KXhzmzin-WCAXcxOXNNWVhhGpNSNarCv1_F8U1a1uiWhZhcQBcinmnKA3cwqjTbeGErOXZe5kmb0JQ7i5k2V0zT07Dl-6Efzf1NFOBd4dAKgfsQuQTHbViQMfErhifAz_WfEb4JSmfQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>198980582</pqid></control><display><type>article</type><title>Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial</title><source>MEDLINE</source><source>EBSCOhost Business Source Complete</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>Julius, Stevo ; Kjeldsen, Sverre E ; Weber, Michael ; Brunner, Hans R ; Ekman, Steffan ; Hansson, Lennart ; Hua, Tsushung ; Laragh, John ; McInnes, Gordon T ; Mitchell, Lada ; Plat, Francis ; Schork, Anthony ; Smith, Beverly ; Zanchetti, Alberto</creator><creatorcontrib>Julius, Stevo ; Kjeldsen, Sverre E ; Weber, Michael ; Brunner, Hans R ; Ekman, Steffan ; Hansson, Lennart ; Hua, Tsushung ; Laragh, John ; McInnes, Gordon T ; Mitchell, Lada ; Plat, Francis ; Schork, Anthony ; Smith, Beverly ; Zanchetti, Alberto ; for the VALUE trial group ; VALUE trial group</creatorcontrib><description>The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.
15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4–2 years.
Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p<0·001 between groups). The primary composite endpoint occurred in 810 patients in the valsartan group (10·6%, 25·5 per 1000 patient-years) and 789 in the amlodipine group (10·4%, 24·7 per 1000 patient-years; hazard ratio 1·04, 95% CI 0·94–1·15, p=0·49).
The main outcome of cardiac disease did not differ between the treatment groups. Unequal reductions in blood pressure might account for differences between the groups in cause-specific outcomes. The findings emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.
Published online June 14, 2004 http://image.thelancet.com/extras/04art4187web.pdf</description><identifier>ISSN: 0140-6736</identifier><identifier>EISSN: 1474-547X</identifier><identifier>DOI: 10.1016/S0140-6736(04)16451-9</identifier><identifier>PMID: 15207952</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>ACE inhibitors ; Age ; Aged ; Amlodipine - adverse effects ; Amlodipine - therapeutic use ; Angina pectoris ; Angioplasty ; Angiotensin II Type 1 Receptor Blockers ; Antihypertensive Agents - adverse effects ; Antihypertensive Agents - therapeutic use ; Antihypertensives ; Blood pressure ; Blood Pressure - drug effects ; Calcium Channel Blockers - adverse effects ; Calcium Channel Blockers - therapeutic use ; Cardiovascular disease ; Cardiovascular diseases ; Cardiovascular Diseases - prevention & control ; Coronary artery disease ; Coronary vessels ; Diabetes ; Diuretics ; Double-Blind Method ; Drug therapy ; Drugs ; Edema ; Endpoint Determination ; Evidence-based medicine ; Female ; Health risk assessment ; Health risks ; Heart attacks ; Heart diseases ; Heart failure ; Heart surgery ; Humans ; Hydrochlorothiazide - therapeutic use ; Hypertension ; Hypertension - drug therapy ; Hypertension - physiopathology ; Hypotheses ; Male ; Measurement techniques ; Medical research ; Middle Aged ; Morbidity ; Mortality ; Patients ; Randomization ; Risk ; Risk Factors ; Side effects ; Sodium Chloride Symporter Inhibitors - therapeutic use ; Stroke ; Tetrazoles - adverse effects ; Tetrazoles - therapeutic use ; Treatment Outcome ; Valine - adverse effects ; Valine - analogs & derivatives ; Valine - therapeutic use ; Valsartan</subject><ispartof>The Lancet (British edition), 2004-06, Vol.363 (9426), p.2022-2031</ispartof><rights>2004 Elsevier Ltd</rights><rights>Copyright Lancet Ltd. Jun 19, 2004</rights><rights>Copyright Elsevier Limited Jun 19, 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c468t-f64cf2db5d7bbca9cac9fa355db7a9c46bb7780e862f9221e17ef155c68c95283</citedby><cites>FETCH-LOGICAL-c468t-f64cf2db5d7bbca9cac9fa355db7a9c46bb7780e862f9221e17ef155c68c95283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/198980582?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,46000,64390,64394,72474</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15207952$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Julius, Stevo</creatorcontrib><creatorcontrib>Kjeldsen, Sverre E</creatorcontrib><creatorcontrib>Weber, Michael</creatorcontrib><creatorcontrib>Brunner, Hans R</creatorcontrib><creatorcontrib>Ekman, Steffan</creatorcontrib><creatorcontrib>Hansson, Lennart</creatorcontrib><creatorcontrib>Hua, Tsushung</creatorcontrib><creatorcontrib>Laragh, John</creatorcontrib><creatorcontrib>McInnes, Gordon T</creatorcontrib><creatorcontrib>Mitchell, Lada</creatorcontrib><creatorcontrib>Plat, Francis</creatorcontrib><creatorcontrib>Schork, Anthony</creatorcontrib><creatorcontrib>Smith, Beverly</creatorcontrib><creatorcontrib>Zanchetti, Alberto</creatorcontrib><creatorcontrib>for the VALUE trial group</creatorcontrib><creatorcontrib>VALUE trial group</creatorcontrib><title>Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial</title><title>The Lancet (British edition)</title><addtitle>Lancet</addtitle><description>The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.
15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4–2 years.
Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p<0·001 between groups). The primary composite endpoint occurred in 810 patients in the valsartan group (10·6%, 25·5 per 1000 patient-years) and 789 in the amlodipine group (10·4%, 24·7 per 1000 patient-years; hazard ratio 1·04, 95% CI 0·94–1·15, p=0·49).
The main outcome of cardiac disease did not differ between the treatment groups. Unequal reductions in blood pressure might account for differences between the groups in cause-specific outcomes. The findings emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.
Published online June 14, 2004 http://image.thelancet.com/extras/04art4187web.pdf</description><subject>ACE inhibitors</subject><subject>Age</subject><subject>Aged</subject><subject>Amlodipine - adverse effects</subject><subject>Amlodipine - therapeutic use</subject><subject>Angina pectoris</subject><subject>Angioplasty</subject><subject>Angiotensin II Type 1 Receptor Blockers</subject><subject>Antihypertensive Agents - adverse effects</subject><subject>Antihypertensive Agents - therapeutic use</subject><subject>Antihypertensives</subject><subject>Blood pressure</subject><subject>Blood Pressure - drug effects</subject><subject>Calcium Channel Blockers - adverse effects</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular diseases</subject><subject>Cardiovascular Diseases - prevention & control</subject><subject>Coronary artery disease</subject><subject>Coronary vessels</subject><subject>Diabetes</subject><subject>Diuretics</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Edema</subject><subject>Endpoint Determination</subject><subject>Evidence-based medicine</subject><subject>Female</subject><subject>Health risk assessment</subject><subject>Health risks</subject><subject>Heart attacks</subject><subject>Heart diseases</subject><subject>Heart failure</subject><subject>Heart surgery</subject><subject>Humans</subject><subject>Hydrochlorothiazide - therapeutic use</subject><subject>Hypertension</subject><subject>Hypertension - drug therapy</subject><subject>Hypertension - physiopathology</subject><subject>Hypotheses</subject><subject>Male</subject><subject>Measurement techniques</subject><subject>Medical research</subject><subject>Middle Aged</subject><subject>Morbidity</subject><subject>Mortality</subject><subject>Patients</subject><subject>Randomization</subject><subject>Risk</subject><subject>Risk Factors</subject><subject>Side effects</subject><subject>Sodium Chloride Symporter Inhibitors - therapeutic use</subject><subject>Stroke</subject><subject>Tetrazoles - adverse effects</subject><subject>Tetrazoles - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Valine - adverse effects</subject><subject>Valine - analogs & derivatives</subject><subject>Valine - therapeutic use</subject><subject>Valsartan</subject><issn>0140-6736</issn><issn>1474-547X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkU1v1DAQhi0EokvhJ4AsuMAhYHv9EXNBVVU-pJV6gCJulmNPGpdNHGxnUf8FPxlvdwUnxGnk0fPOaPwg9JSS15RQ-eYzoZw0Uq3lS8JfUckFbfQ9tKJc8UZw9e0-Wv1BTtCjnG8IIVwS8RCdUMGI0oKt0K_Lpbg4QsZhwsPtDKnAlMMO8GxLgKlkbAsewvWAnU0-xJ3NbtnahFPI33FJYAt4_DOUASe4DmNN487m2osT3tlttqnYCceE7biNPsxhgre4DIC_nm2uLnCyk49j2AdKCnb7GD3oawqeHOspunp_8eX8Y7O5_PDp_GzTOC7b0vSSu575TnjVdc5qZ53u7VoI36n64rLrlGoJtJL1mjEKVEFPhXCydfXwdn2KXhzmzin-WCAXcxOXNNWVhhGpNSNarCv1_F8U1a1uiWhZhcQBcinmnKA3cwqjTbeGErOXZe5kmb0JQ7i5k2V0zT07Dl-6Efzf1NFOBd4dAKgfsQuQTHbViQMfErhifAz_WfEb4JSmfQ</recordid><startdate>20040619</startdate><enddate>20040619</enddate><creator>Julius, Stevo</creator><creator>Kjeldsen, Sverre E</creator><creator>Weber, Michael</creator><creator>Brunner, Hans R</creator><creator>Ekman, Steffan</creator><creator>Hansson, Lennart</creator><creator>Hua, Tsushung</creator><creator>Laragh, John</creator><creator>McInnes, Gordon T</creator><creator>Mitchell, Lada</creator><creator>Plat, Francis</creator><creator>Schork, Anthony</creator><creator>Smith, Beverly</creator><creator>Zanchetti, Alberto</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TT</scope><scope>0TZ</scope><scope>0U~</scope><scope>3V.</scope><scope>7QL</scope><scope>7QP</scope><scope>7RV</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88C</scope><scope>88E</scope><scope>88G</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8C1</scope><scope>8C2</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>ASE</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FPQ</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K6X</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>KB~</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>S0X</scope></search><sort><creationdate>20040619</creationdate><title>Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial</title><author>Julius, Stevo ; Kjeldsen, Sverre E ; Weber, Michael ; Brunner, Hans R ; Ekman, Steffan ; Hansson, Lennart ; Hua, Tsushung ; Laragh, John ; McInnes, Gordon T ; Mitchell, Lada ; Plat, Francis ; Schork, Anthony ; Smith, Beverly ; Zanchetti, Alberto</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c468t-f64cf2db5d7bbca9cac9fa355db7a9c46bb7780e862f9221e17ef155c68c95283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>ACE inhibitors</topic><topic>Age</topic><topic>Aged</topic><topic>Amlodipine - adverse effects</topic><topic>Amlodipine - therapeutic use</topic><topic>Angina pectoris</topic><topic>Angioplasty</topic><topic>Angiotensin II Type 1 Receptor Blockers</topic><topic>Antihypertensive Agents - adverse effects</topic><topic>Antihypertensive Agents - therapeutic use</topic><topic>Antihypertensives</topic><topic>Blood pressure</topic><topic>Blood Pressure - drug effects</topic><topic>Calcium Channel Blockers - adverse effects</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular diseases</topic><topic>Cardiovascular Diseases - prevention & control</topic><topic>Coronary artery disease</topic><topic>Coronary vessels</topic><topic>Diabetes</topic><topic>Diuretics</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Edema</topic><topic>Endpoint Determination</topic><topic>Evidence-based medicine</topic><topic>Female</topic><topic>Health risk assessment</topic><topic>Health risks</topic><topic>Heart attacks</topic><topic>Heart diseases</topic><topic>Heart failure</topic><topic>Heart surgery</topic><topic>Humans</topic><topic>Hydrochlorothiazide - therapeutic use</topic><topic>Hypertension</topic><topic>Hypertension - drug therapy</topic><topic>Hypertension - physiopathology</topic><topic>Hypotheses</topic><topic>Male</topic><topic>Measurement techniques</topic><topic>Medical research</topic><topic>Middle Aged</topic><topic>Morbidity</topic><topic>Mortality</topic><topic>Patients</topic><topic>Randomization</topic><topic>Risk</topic><topic>Risk Factors</topic><topic>Side effects</topic><topic>Sodium Chloride Symporter Inhibitors - therapeutic use</topic><topic>Stroke</topic><topic>Tetrazoles - adverse effects</topic><topic>Tetrazoles - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Valine - adverse effects</topic><topic>Valine - analogs & derivatives</topic><topic>Valine - therapeutic use</topic><topic>Valsartan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Julius, Stevo</creatorcontrib><creatorcontrib>Kjeldsen, Sverre E</creatorcontrib><creatorcontrib>Weber, Michael</creatorcontrib><creatorcontrib>Brunner, Hans R</creatorcontrib><creatorcontrib>Ekman, Steffan</creatorcontrib><creatorcontrib>Hansson, Lennart</creatorcontrib><creatorcontrib>Hua, Tsushung</creatorcontrib><creatorcontrib>Laragh, John</creatorcontrib><creatorcontrib>McInnes, Gordon T</creatorcontrib><creatorcontrib>Mitchell, Lada</creatorcontrib><creatorcontrib>Plat, Francis</creatorcontrib><creatorcontrib>Schork, Anthony</creatorcontrib><creatorcontrib>Smith, Beverly</creatorcontrib><creatorcontrib>Zanchetti, Alberto</creatorcontrib><creatorcontrib>for the VALUE trial group</creatorcontrib><creatorcontrib>VALUE trial group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>News PRO</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Global News & ABI/Inform Professional</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health Medical collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Lancet Titles</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>British Nursing Index</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>British Nursing Index (BNI) (1985 to Present)</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Index</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Newsstand Professional</collection><collection>ProQuest Biological Science Collection</collection><collection>Family Health Database (Proquest)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management Database</collection><collection>PML(ProQuest Medical Library)</collection><collection>Psychology Database (ProQuest)</collection><collection>ProQuest Research Library</collection><collection>ProQuest Science Journals</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><jtitle>The Lancet (British edition)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Julius, Stevo</au><au>Kjeldsen, Sverre E</au><au>Weber, Michael</au><au>Brunner, Hans R</au><au>Ekman, Steffan</au><au>Hansson, Lennart</au><au>Hua, Tsushung</au><au>Laragh, John</au><au>McInnes, Gordon T</au><au>Mitchell, Lada</au><au>Plat, Francis</au><au>Schork, Anthony</au><au>Smith, Beverly</au><au>Zanchetti, Alberto</au><aucorp>for the VALUE trial group</aucorp><aucorp>VALUE trial group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial</atitle><jtitle>The Lancet (British edition)</jtitle><addtitle>Lancet</addtitle><date>2004-06-19</date><risdate>2004</risdate><volume>363</volume><issue>9426</issue><spage>2022</spage><epage>2031</epage><pages>2022-2031</pages><issn>0140-6736</issn><eissn>1474-547X</eissn><coden>LANCAO</coden><abstract>The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial was designed to test the hypothesis that for the same blood-pressure control, valsartan would reduce cardiac morbidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.
15 245 patients, aged 50 years or older with treated or untreated hypertension and high risk of cardiac events participated in a randomised, double-blind, parallel-group comparison of therapy based on valsartan or amlodipine. Duration of treatment was event-driven and the trial lasted until at least 1450 patients had reached a primary endpoint, defined as a composite of cardiac mortality and morbidity. Patients from 31 countries were followed up for a mean of 4–2 years.
Blood pressure was reduced by both treatments, but the effects of the amlodipine-based regimen were more pronounced, especially in the early period (blood pressure 4·0/2·1 mm Hg lower in amlodipine than valsartan group after 1 month; 1·5/1·3 mm Hg after 1 year; p<0·001 between groups). The primary composite endpoint occurred in 810 patients in the valsartan group (10·6%, 25·5 per 1000 patient-years) and 789 in the amlodipine group (10·4%, 24·7 per 1000 patient-years; hazard ratio 1·04, 95% CI 0·94–1·15, p=0·49).
The main outcome of cardiac disease did not differ between the treatment groups. Unequal reductions in blood pressure might account for differences between the groups in cause-specific outcomes. The findings emphasise the importance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.
Published online June 14, 2004 http://image.thelancet.com/extras/04art4187web.pdf</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>15207952</pmid><doi>10.1016/S0140-6736(04)16451-9</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0140-6736 |
| ispartof | The Lancet (British edition), 2004-06, Vol.363 (9426), p.2022-2031 |
| issn | 0140-6736 1474-547X |
| language | eng |
| recordid | cdi_proquest_journals_2069920953 |
| source | MEDLINE; EBSCOhost Business Source Complete; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland |
| subjects | ACE inhibitors Age Aged Amlodipine - adverse effects Amlodipine - therapeutic use Angina pectoris Angioplasty Angiotensin II Type 1 Receptor Blockers Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Antihypertensives Blood pressure Blood Pressure - drug effects Calcium Channel Blockers - adverse effects Calcium Channel Blockers - therapeutic use Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - prevention & control Coronary artery disease Coronary vessels Diabetes Diuretics Double-Blind Method Drug therapy Drugs Edema Endpoint Determination Evidence-based medicine Female Health risk assessment Health risks Heart attacks Heart diseases Heart failure Heart surgery Humans Hydrochlorothiazide - therapeutic use Hypertension Hypertension - drug therapy Hypertension - physiopathology Hypotheses Male Measurement techniques Medical research Middle Aged Morbidity Mortality Patients Randomization Risk Risk Factors Side effects Sodium Chloride Symporter Inhibitors - therapeutic use Stroke Tetrazoles - adverse effects Tetrazoles - therapeutic use Treatment Outcome Valine - adverse effects Valine - analogs & derivatives Valine - therapeutic use Valsartan |
| title | Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T18%3A23%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Outcomes%20in%20hypertensive%20patients%20at%20high%20cardiovascular%20risk%20treated%20with%20regimens%20based%20on%20valsartan%20or%20amlodipine:%20the%20VALUE%20randomised%20trial&rft.jtitle=The%20Lancet%20(British%20edition)&rft.au=Julius,%20Stevo&rft.aucorp=for%20the%20VALUE%20trial%20group&rft.date=2004-06-19&rft.volume=363&rft.issue=9426&rft.spage=2022&rft.epage=2031&rft.pages=2022-2031&rft.issn=0140-6736&rft.eissn=1474-547X&rft.coden=LANCAO&rft_id=info:doi/10.1016/S0140-6736(04)16451-9&rft_dat=%3Cproquest_cross%3E657591711%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=198980582&rft_id=info:pmid/15207952&rft_els_id=S0140673604164519&rfr_iscdi=true |